cancer

The National Institute for Health and Clinical Excellence (Nice) has taken responsibility for helping the NHS to optimise its use of medicines with its absorption of the National Prescribing Centre (NPC).

Bupa has announced it will no longer sell corporate private medical insurance (PMI) schemes which feature overall cost or time limits for cancer treatment.

The NHS has made significant progress in improving important aspects of its cancer care over the last decade, according to MPs.

The National Institute for Health and Clinical Excellence (Nice) has rejected the use of Avastin for metastatic breast cancer on the NHS.

Does the external rating of products add value and what can advisers use them for? Ben Heffer explains

NHS cancer patients are generally positive about their care experiences although there is scope for improvements, according to a new survey for the organisation.

International private medical insurer InterGlobal is introducing an UltraCare Elite Plan for 2011 including enhanced benefits for cancer care.

Improvements have been made in cancer care since 2007, however, lack of information on costs and outcomes inhibits improvements, according to an National Audit Office (NAO) report.

The House of Lords has held a debate on the impact that private medical insurers' reimbursement policies have on cancer patients.

A £200m per year cancer drugs fund for the NHS has been confirmed by the government.